drugset / Trial / NCT06036914

A Study of Ultra High Dose Diuretics to Treat Heart Failure

NCT06036914

Phase 2 Completed 20 enrolled Mayo Clinic
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the safety and effectiveness of ultrahigh dose diuretics compared to standard dose diuretics over 24 hours in patients with decompensated heart failure.

Timeline

Start
2023-11-27
Primary completion
2024-10-08
Completion
2024-10-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Bumetanide Small molecule 12.5 mg Intravenous
Comparator Furosemide Other / unclassified 40 mg Intravenous
Comparator Furosemide Other / unclassified 100 mg Intravenous

Indications